Recursion Pharmaceuticals' stock soared by 20.13% on Friday, closing at $5.49 per share after introducing Boltz-2, an advanced AI model for predicting binding affinity.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
